RPL3L

Across TCGA pan-cancer cohorts, RPL3L mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RPL3L’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where RPL3L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RPL3L is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

PDAC, HNSC, and LSCC are the cancer types where RPL3L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL3L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	All	−1.763	<.001	8	view →
HNSC	Male	II,III,IV	−1.124	<.001	8	view →
LSCC	Female	All	−0.540	.032	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

RPL3L–PDAC

Open the PDAC breakdown →